Sara Paul
Nurse Practitioner · Conover, NCNPI 1841253820
Payments from drug & device makers
Across 102 payments — averaging $106.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$9K
- AstraZeneca$677
- E.r. Squibb & Sons, L.L.C.$317
- Novartis$298
- Boehringer Ingelheim$189
- Medtronic$139
- plus $696 from 12 others
What the payments were for
- Consulting fees$7,95673%
- Travel & lodging$530%
- Food & beverage$2,85826%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 18 | $8,551 |
| AstraZeneca | 12 | $677 |
| E.r. Squibb & Sons, L.L.C. | 13 | $317 |
| Novartis | 14 | $298 |
| Boehringer Ingelheim | 6 | $189 |
| Medtronic | 4 | $139 |
| Actelion Pharmaceuticals US, Inc. | 4 | $127 |
| Pfizer | 7 | $118 |
| Merck | 6 | $91 |
| Amgen | 5 | $86 |
| Johnson & Johnson | 2 | $67 |
| Impulse Dynamics (USA) Inc. | 1 | $51 |
| Scpharmaceuticals Inc. | 2 | $32 |
| Cvrx, Inc. | 2 | $32 |
| Boston Scientific | 2 | $31 |
| Novo Nordisk | 2 | $27 |
| Irhythm Technologies, Inc. | 1 | $19 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CARDIOMEMS$4,640
- CardioMEMS HF System$3,533
- FARXIGA$342
- LOKELMA$125
- CAMZYOS$123
How this compares
$10,867 in reported general payments places this provider in the 95th percentile of 4,393 nurse practitioner providers in North Carolina.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EntrestoSacubitril/Valsartan | 79 | $75,065 |
| EliquisApixaban | 74 | $59,172 |
| JardianceEmpagliflozin | 64 | $48,363 |
| FarxigaDapagliflozin Propanediol | 25 | $17,244 |
| XareltoRivaroxaban | 15 | $11,098 |
| Metoprolol Succinate | 113 | $1,223 |
| Spironolactone | 101 | $511 |
| Torsemide | 18 | $303 |
| Potassium Chloride | 23 | $303 |
| Furosemide | 63 | $281 |
| Atorvastatin Calcium | 44 | $236 |
| SotalolSotalol Hcl | 18 | $211 |
| Losartan Potassium | 36 | $168 |
| Digoxin | 14 | $156 |
| Carvedilol | 32 | $139 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisEntresto | $298 | $75,06579 claims |
| PfizerEliquis | $118 | $59,17274 claims |
| Boehringer IngelheimJardiance | $189 | $48,36364 claims |
| AstraZenecaFarxiga | $677 | $17,24425 claims |
| Johnson & JohnsonXarelto | $67 | $11,09815 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,393 nurse practitioner providers in North Carolina.
Other nurse practitioner in Conover
- Sandrivette JohnsonRaleigh$573K
- Skyler RogersPinehurst$174K
- Jamie DinerDurham$170K
- Ayeshia WrightMocksville$145K
- Deborah AllenDurham$112K
- Jeanann VawterGastonia$97K
- Terra KampJacksonville$72K
- Mary DilorenzoCharlotte$71K
- Olivia OgburnWinston Salem$70K
- Bridget ArchambaultDurham$57K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.